Abstract: Objective To compare the effect of allogeneic hematopoietic stem cell transplantation(allo-HSCT) between human leucocyte antigen(HLA)-matched donor and haploidentical donor(HID) in the treatment of transfusion-dependent non-severe aplastic anemia(TD-NSAA). 
Methods Clinical data of 14 TD-NSAA patients treated with allo-HSCT were retrospectively analyzed, and they were divided into HID group and HLA-matched donor related or unrelated donor(MR/UD) group according to donor origin. Implantation rate, implantation time, transplantation-related death, transplantation-related complications, and overall survival(OS) of two groups were compared, and the efficacy of two methods in the treatment of TD-NSAA was evaluated. 
Results The incidence of acute graft-versus-host-disease(aGVHD) in HID group was higher than that in MR/UD group(P＜0.05), which was mainly reflected in aGVHD of Ⅰ-Ⅱ. There were no significant differences in medical history, hematopoietic stem cell count, survival time after hematopoietic stem cell transplant, chimeric status, transplant-related complications(except Ⅰ-Ⅱ aGVHD), 3-year OS,OS and disease-free survival between two groups(P＞0.05). 
Conclusion The efficacy of HID allo-HSCT in TD-NSAA is comparable to that of MR/UD, and HID allo-HSCT should be considered in patients who were not successfully matched in the myeloid bank or sibling donor. 

Key words: anemia, aplastic, hematopoietic stem cell transplantation, donor selection